Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Other Non-current Assets
Long-term assets not reported separately.
Sagimet Biosciences Inc.NASDAQ: SGMT
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets remains negative
Q1 FY2026 other non-current assets was $0, compared with $62K a year earlier.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 27K | +0.0% |
| FY2021 | 2021-12-31 | 27K | — |
Other Non-current Assets vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 other non-current assets of $0 is the lowest of the 11 companies compared; the peer median is $1.77M.
- Its year-over-year change of -100.0% is the lowest of 11, against a peer median of -24.9%.
- Other non-current assets amounts to 0.0% of total assets for SGMT, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $42.19B | +5202413.6% | +291.0% | 19.6% | |
| Mar 2026 | $32.92M | +1045.3% | +74.0% | 15.0% | |
| Mar 2026 | $3.38M | -19.3% | -28.4% | 1.0% | |
| Mar 2026 | $3.05M | -30.6% | +28.0% | 1.1% | |
| Mar 2026 | $2.03M | -89.0% | — | 0.8% | |
ZURAZura Bio Limited | Mar 2026 | $1.51M | +116.6% | -24.3% | 0.7% |
| Mar 2026 | $672K | -98.7% | — | 0.6% | |
| Mar 2026 | $312K | +0.0% | -29.5% | 0.1% | |
| Mar 2026 | $30K | -90.0% | — | 0.1% | |
| Mar 2026 | $3K | -99.8% | -21.1% | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding SGMT) | $1.77M | -24.9% | -21.1% | 0.7% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.